La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

EDAP TMS Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Ryan Rhodes

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.4yrs
Proprietà del CEO	n/a
Durata media del management	1.4yrs
Durata media del Consiglio di amministrazione	1.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Ryan Rhodes (62 yo)

1.4yrs

Mandato

Mr. Ryan Rhodes serves as Chief Executive Officer of EDAP TMS S.A. since May 01, 2023 and serves as Director since August 23, 2023. He served as Chief Executive Officer and President of Venus Concept Inc....

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ryan Rhodes	CEO & Director	1.4yrs	Nessun dato	Nessun dato
Ken Mobeck	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Carre Emmanuel	Chief Operating Officer	no data	Nessun dato	Nessun dato
Francois Dietsch	Chief Accounting Officer	less than a year	Nessun dato	Nessun dato
Blandine Confort	Head of Legal Affairs & Investor Relations and Secretary	no data	Nessun dato	Nessun dato
Frederic Pech	President of EDAP TMS France	1.4yrs	Nessun dato	Nessun dato
Jean-Francois Bachelard	President & Chief Executive Officer of Edaptechnomed Co. Ltd.	15.8yrs	Nessun dato	Nessun dato

1.4yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di EDA non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Ryan Rhodes	CEO & Director	1.2yrs	Nessun dato	Nessun dato
Lance Willsey	Independent Chairman of the Board of Director	less than a year	Nessun dato	Nessun dato
Pierre Beysson	Independent Director	22.1yrs	Nessun dato	Nessun dato
Marie Meynadier	Independent Director	4.3yrs	Nessun dato	Nessun dato
Fran Schulz	Director	less than a year	Nessun dato	Nessun dato

1.2yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di EDA non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.

EDAP TMS Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

EDAP TMS S.A. Announces Resignation of Marc Oczachowski as Chairman of Board of Directors, Effective September 30, 2024

EDAP TMS S.A. Appoints Fran Schulz to Board of Directors

EDAP TMS S.A. Appoints Ken Mobeck as Chief Financial Officer

Less than half of directors are independent

EDAP TMS S.A. Announces Board Changes

EDAP TMS S.A. Announces Board Changes

Recent updates

EDAP TMS S.A. Announces First Patients Treated in Phase I/Ii Study Evaluating Focal One Robotic Hifu for the Treatment of Benign Prostatic Hyperplasia (Bph)

New minor risk - Market cap size

Second quarter 2024 earnings released: €0.17 loss per share (vs €0.13 loss in 2Q 2023)

EDAP TMS S.A. Announces Resignation of Marc Oczachowski as Chairman of Board of Directors, Effective September 30, 2024

New minor risk - Share price stability

EDAP TMS S.A. to Report Q2, 2024 Results on Aug 28, 2024

EDAP TMS S.A. Announces Interim Results from Phase 3 Study Evaluating Robotic Hifu for the Treatment of Deep Infiltrating Endometriosis

EDAP TMS S.A. Appoints Fran Schulz to Board of Directors

First quarter 2024 earnings released: €0.12 loss per share (vs €0.20 loss in 1Q 2023)

EDAP TMS S.A. to Report Q1, 2024 Results on May 16, 2024

Full year 2023 earnings released: €0.57 loss per share (vs €0.085 loss in FY 2022)

EDAP TMS S.A. to Report Q4, 2023 Results on Mar 27, 2024

EDAP TMS SA Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis

EDAP TMS S.A. Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One Hifu Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

EDAP TMS S.A. Appoints Ken Mobeck as Chief Financial Officer

Less than half of directors are independent

EDAP TMS S.A. Announces Board Changes

Third quarter 2023 earnings released: €0.11 loss per share (vs €0 in 3Q 2022)

EDAP TMS S.A. to Report Q3, 2023 Results on Nov 09, 2023

New minor risk - Profitability

Second quarter 2023 earnings released: €0.13 loss per share (vs €0.055 profit in 2Q 2022)

EDAP TMS S.A. Announces Board Changes

New major risk - Revenue and earnings growth

EDAP TMS S.A. to Report Q2, 2023 Results on Aug 24, 2023

Insufficient new directors

EDAP TMS S.A., Annual General Meeting, Jun 30, 2023

First quarter 2023 earnings released: €0.20 loss per share (vs €0.011 profit in 1Q 2022)

EDAP TMS S.A. to Report Q1, 2023 Results on May 17, 2023

Full year 2022 earnings released: €0.085 loss per share (vs €0.022 profit in FY 2021)

EDAP TMS SA Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound for the Treatment of Rectal Endometriosis

Now 23% undervalued

Now 22% undervalued

EDAP TMS S.A. Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis

Third quarter 2022 earnings released

EDAP TMS S.A. to Report Q3, 2022 Results on Nov 16, 2022

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

Second quarter 2022 earnings released: EPS: €0.055 (vs €0.013 loss in 2Q 2021)

EDAP TMS S.A. to Report Q2, 2022 Results on Aug 24, 2022

EDAP TMS S.A., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: EPS: €0.011 (vs €0.026 in 1Q 2021)

EDAP TMS S.A. to Report Q1, 2022 Results on May 17, 2022

EDAP TMS S.A. to Showcase Its Focal One® Platform At the Annual Meeting of the American Urological Association

Full year 2021 earnings released: EPS: €0.021 (vs €0.058 loss in FY 2020)

EDAP TMS S.A. to Report Q4, 2021 Results on Mar 30, 2022

EDAP Announces Publication of Positive Pre-clinical Results Using Intraoperative HIFU Ablation of the Pancreas in the Journal Cancers

Third quarter 2021 earnings released: €0.03 loss per share (vs €0.034 loss in 3Q 2020)

Mega Elektroniikka Oy agreed to acquire a 25% stake in Technomed Medical Systems S.A from EDAP TMS S.A. (NasdaqGM : EDAP).

Second quarter 2021 earnings released: €0.013 loss per share (vs €0.006 loss in 2Q 2020)

EDAP TMS S.A. Provides Unaudited Earnings Guidance for the Second Quarter of 2021

First quarter 2021 earnings released: EPS €0.026 (vs €0.045 loss in 1Q 2020)

EDAP TMS S.A. Provides Earnings Guidance for the First Quarter Ended March 31, 2021

Full year 2020 earnings released: €0.058 loss per share (vs €0.052 profit in FY 2019)

New 90-day high: €6.50

EDAP Announces Positive Interim Results of French Urology Association Sponsored Clinical Study Comparing HIFU to Radical Prostate Surgery

New 90-day high: €4.60

New 90-day high: €4.20

Third quarter 2020 earnings released: €0.034 loss per share

Revenue beats expectations

EDAP TMS SA Announces the Company Signs an Exclusive Distribution Agreement with AB Medica

EDAP TMS S.A. to Report Q3, 2020 Results on Nov 18, 2020

New 90-day high: €4.06

New 90-day high: €3.98

New 90-day high - €3.00

First half earnings released

EDAP TMS S.A. to Report Q2, 2020 Results on Aug 26, 2020

New 90-day high - €2.80

AMMINISTRATORE DELEGATO

Mandato